Elixir Pharmaceuticals Inc.
This article was originally published in Start Up
Executive Summary
Lenny Guarente, PhD, in a molecular genetics laboratory at the Massachusetts Institute of Technology, has found single gene mutations that appear to double the life span of single-celled yeast. Cynthia Kenyon, PhD, a biochemist with the University of California, has found a similar gene that appears to contribute to long life in roundworms. Elixir Pharmaceuticals Inc. was founded to apply the research of Guarente and Kenyon to that higher-order, two-legged mammal known as man.
You may also be interested in...
Mining the Mitochondria for Clues to Cell Survival Mechanisms
Researchers have identified a protein in the mitochondria -- where cells generate the energy needed to drive biological processes -- that is dramatically upregulated by nutrient restriction. It appears to protect the cell from stress, in keeping with observations that caloric restriction diets slow aging. The researchers go on to show that a set of other proteins activated in turn by this process may be targets for the development of therapies for neurodegenerative diseases and diabetes.
Mining the Mitochondria for Clues to Cell Survival Mechanisms
Researchers have identified a protein in the mitochondria -- where cells generate the energy needed to drive biological processes -- that is dramatically upregulated by nutrient restriction. It appears to protect the cell from stress, in keeping with observations that caloric restriction diets slow aging. The researchers go on to show that a set of other proteins activated in turn by this process may be targets for the development of therapies for neurodegenerative diseases and diabetes.
Profiles of Two Iconoclasts
In recent years, most venture capital firms have focused on investing in companies with well-developed product pipelines. In this issue of START-UP, we profile two trendsetters: Fred Cohen, managing director at Texas Pacific Group Ventures; and Christoph Westphal, formerly a partner at Polaris Ventures and now vice chairman and CEO of Sirtris Pharmaceuticals. Both men are physician scientists turned investors, who have tapped into their scientific and clinical knowledge to make investments in "high concept" discovery stage companies. And although the investments are intriguing, it's too early to say whether or not the strategies adopted by these two men will yield returns for their backers.